Browse the corpus

Emicizumab is a medication used in the management and treatment of hemophilia A. It belongs to the bispecific monoclonal antibody class of drugs. Managing patients with HA is complex and requires replacing FVIII for bleeding prophylaxis and treating acute bleeding episodes. Emicizumab was created to circumvent challenges associated with frequent intravenous administration of FVIII and offer a standardized treatment option for Hemophilia A patients with and without inhibitors. This activity reviews the indications, mechanism of action, and adverse events associated with emicizumab administration in treating hemophilia A. This activity also highlights drug monitoring and relevant interferences with coagulation assays, which are pertinent for interprofessional team members in managing patients with hemophilia A. Objectives: Describe some benefits of emicizumab in comparison to prior treatments for hemophilia A. Identify the mechanism of action of emicizumab and how it may affect laboratory testing. Review the rationale behind proper assay ordering practices in patients receiving emicizumab prophylaxis. Summarize how the interprofessional team can coordinate care to reduce complications associated with emicizumab to obtain better patient outcomes. Access free multiple choice questions on this topic.

Using previous trials like HAVEN, an efficacious range for emicizumab is 30 to 70 microgram/milliliter.[22] Management of breakthrough bleeding is a potent concern.[28] Currently, there is no antidote to emicizumab. Carcinogenesis, Mutagenesis, Impairment of Fertility: Studies in animals investigating the carcinogenic effects of emicizumab have not been conducted. However, emicizumab did not cause any toxicological changes in the reproductive organs in preclinical studies, with the dose of 30 mg/kg/week in subcutaneous toxicity studies of twenty-six weeks duration and a dose of 100 mg/kg/week for four-week intravenous toxicity study.

Researchers performed the HAVEN 2 trial on children with hemophilia with inhibitor development. Typically they develop inhibitors within 50 days of Factor VIII therapy. Children with hemophilia require high-volume infusions requiring a central venous access device (CVAD), which can lead to increased possibilities of infection/thrombosis.[11] The study revealed that once a week, subcutaneous injection decreased annual bleeding rates in children with hemophilia A with Factor VIII inhibitor by 99%.[11] [Level 1] An open study was conducted in children with one treatment arm receiving emicizumab and the other with no inhibitors. Results supported a decrease in bleeding events throughout the year. It also supported decreased anxiety associated with possible bleed causes, including activity levels. Subjects reported increased physical activity during the trial. Patients received either 2-week dosing or 4-week dosing. Both regimens showed an appropriate decrease in bleeding and disruption in daily living.[12] [Level 2] Regarding adults with hemophilia A and no inhibitors, dosing once every four weeks is adequate for bleeding control and well tolerated by patients. [Level 3].[29] Overall, emicizumab is generally well-tolerated and has versatile dosing options, including once every 1, 2, or 4 weeks. This novel drug allows an alternative to conventional Factor VIII replacement products in patients with hemophilia A, with or without the presence of inhibitors.[14] [Level 5]

Regarding adults with hemophilia A and no inhibitors, dosing once every four weeks is adequate for bleeding control and well tolerated by patients. [Level 3].[29] Overall, emicizumab is generally well-tolerated and has versatile dosing options, including once every 1, 2, or 4 weeks. This novel drug allows an alternative to conventional Factor VIII replacement products in patients with hemophilia A, with or without the presence of inhibitors.[14] [Level 5] Typically emicizumab will be prescribed by a hematologist, but it still requires the efforts of an entire interprofessional team. Management of hemophilia requires comprehensive diagnostic and treatment services, pain control, patient education, and genetic, psychosocial, and vocational counseling. The Centers for Disease Control and Prevention(CDC) operates in collaboration with the U.S. Hemophilia Treatment Center Network (USHTCN), a federally funded, specialized health care center called hemophilia treatment centers or HTCs. HTC are specialized, multidisciplinary healthcare centers with expertise in providing care for Patients with Hemophilia(PWH). To achieve this goal, a core interprofessional team consisting of a hematologist, certified pediatric hematology-oncology nurse, physical therapist, social worker, and a comprehensive multidisciplinary team including pediatricians, internists, orthopedic surgeons, dentists, genetic counselors, pharmacists, nutritionists, vocational rehabilitation counselors, and other healthcare providers all play a vital role in the care of the patient with hemophilia. This interprofessional care provided by HTCs optimizes patient outcomes and health-related quality of life (HRQoL) in patients with hemophilia by decreasing the probability of serious adverse events.[30] The interprofessional model includes open communication between all team members, as well as meticulous documentation of all patient interactions is the responsibility of all team members, so everyone managing the case has the most accurate and up-to-date patient data.[ This interprofessional paradigm will optimize therapy with emicizumab and the overall case management. Level 5]